Key Takeaways
- CRSP shares declined by as much as 11.59% during Friday’s session, touching an intraday low of $51.21
- First quarter results disappointed significantly: loss per share of -$1.37 versus analyst expectations of -$1.15; revenues of $0.86M compared to forecasts of $4.72M — representing a 97.8% year-over-year decline
- Competitive headwinds emerged as Regeneron announced its newly authorized gene therapy, Otarmeni, would be provided at no cost to qualifying patients in the United States, creating questions about Casgevy’s pricing sustainability
- Chief Executive Samarth Kulkarni divested 10,349 shares on March 16; company insiders collectively sold 51,828 shares during the previous three-month period
- Wall Street analysts continue to rate the stock as a consensus “Moderate Buy” with a mean price objective of $64.53
CRISPR Therapeutics ($CRSP) experienced a challenging trading session on Friday. Shares plummeted by as much as 11.59%, reaching an intraday bottom of $51.21, before closing near $51.04 — a significant decline from the previous day’s close of $55.18. Trading volume registered approximately 1.36 million shares, running about 27% lighter than typical daily activity.
CRISPR Therapeutics AG, CRSP
The sharp downturn stemmed from a confluence of negative catalysts: disappointing quarterly financial results and emerging competitive dynamics from Regeneron.
Regarding financial performance, CRISPR disclosed a loss per share of -$1.37 for the most recent quarter, falling short of Wall Street’s consensus projection of -$1.15. Revenues registered a mere $0.86 million — substantially below analyst forecasts of $4.72 million. This represented a staggering 97.8% contraction compared to the same period last year, surprising market participants.
The biotechnology firm’s return on equity remains negative at -26.31%, while its net margin continues to reflect deep losses. Wall Street analysts are currently projecting a full-year loss per share of -$4.93.
Regeneron’s Complimentary Gene Therapy Creates Competitive Headwinds
The secondary catalyst weighing on shares involves Regeneron’s latest development. The pharmaceutical company secured regulatory authorization for Otarmeni, a gene therapy it intends to distribute without charge to qualified U.S. patients. This represents a significant challenge to the broader gene-editing industry.
CRISPR’s primary commercial product, Casgevy — co-developed alongside Vertex Pharmaceuticals — commands a list price of $2.2 million. Investors are concerned that Regeneron’s zero-cost distribution strategy could reshape pricing dynamics throughout the sector, making it increasingly difficult for high-priced single-administration treatments to defend their valuations.
Casgevy achieved recognition as the inaugural CRISPR-based treatment to receive FDA authorization, representing a historic achievement. However, commercial adoption has progressed slower than anticipated, and Regeneron’s competitive move introduces additional questions regarding the revenue trajectory.
Executive Stock Sales Contribute to Investor Anxiety
Recent insider transactions haven’t bolstered investor confidence. Chief Executive Samarth Kulkarni disposed of 10,349 shares on March 16 at an average transaction price of $48.26, trimming his holdings by approximately 4%. General Counsel James Kasinger simultaneously sold 3,450 shares on the identical date.
During the preceding three-month window, company insiders have collectively divested 51,828 shares, generating approximately $2.58 million in proceeds. Internal stakeholders currently control 4.30% of outstanding shares.
While such divestment activity isn’t uncommon among biotech executives managing equity-based compensation packages, it contributes to the cautious atmosphere surrounding the shares.
From an analyst perspective, the outlook remains somewhat divided but generally supportive. Bank of America maintains a Buy recommendation with an $89 price objective. Needham carries a Buy rating alongside an $82 target. TD Cowen holds a neutral Hold stance with a $45 projection. Citizens JMP assigns a Market Outperform rating with an $80 target. The aggregate consensus lands at Moderate Buy, featuring an average price target of $64.53 — considerably above present trading levels.
The equity’s 50-day moving average registers at $52.68 while the 200-day average stands at $55.70. The company’s market capitalization approximates $4.90 billion with a beta coefficient of 1.80.
Current price action shows CRSP trading around $51, remaining beneath both critical moving average benchmarks.
The post CRISPR Therapeutics (CRSP) Stock Plunges 11% Amid Earnings Disappointment and Competitive Threat appeared first on Blockonomi.
Source: https://blockonomi.com/crispr-therapeutics-crsp-stock-plunges-11-amid-earnings-disappointment-and-competitive-threat/
